Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Bioequivalence of Tulisokibart Autoinjectors in Healthy Participants
NCT07405177Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tulisokibart in inflammatory bowel disease (IBD) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity at 14 weeks, Area Under the Concentration-Time Curve from Time 0 to Last at 14 weeks and 1 more. Started Mar 2026; status: completed.
02
Drugs
tulisokibart
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07405177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07405177.